| DON'T BUY | 11.450 | David Baskin | Eugene Melnyk's challenge of the Board of Directors was withdrawn and very positive for the stock. Jury is out on whether they have sufficient drugs in the pipeline to turn it into a growth company. Would prefer others in generic drugs such as Teva (TEVA-Q). | 2008-09-02 | |
| Comment | 10.700 | Brian Acker, CA | Hasn't been in his portfolio for several years. Plagued with bad news. Just needs some good news somewhere. Model price is $21.27, a positive 100% differential. He is seeing a little bit of traction in this group. | 2008-08-06 | |
| DON'T BUY | 9.990 | Benj Gallander | Has many internal difficulties. A company that is very hard for him to understand what is going on. | 2008-07-04 | |
| DON'T BUY | 10.820 | Laura Wallace | Has had a very chequered history. Base business is quite attractive. With all the controversy surrounding it she would wait until things settle down. | 2008-06-18 | |
| DON'T BUY | 11.790 | Duncan Stewart | Doesn't like their old strategy of trying to make “hard to manufacture” generics. New management has a completely viable strategy focusing on high-value add central nervous system drugs. However, they have never shown any skill set and it's a very competitive market. | 2008-06-03 | |
| DON'T BUY | 11.560 | Robert Floyd | Showing declining revenues. Volatile sector – been a disaster in past years. This stock is ahead in this sector but will face generics. Revenue profile is declining. Could add to position as a value play. Doesn’t like the sector. | 2008-05-30 | |
| DON'T BUY | 11.900 | David Baskin | Having fights about who’s going to be on the board and who’s going to run the show. Doesn’t like companies with this kind of dissension. 12.5% dividend and the market is saying that is unsustainable. | 2008-05-27 | |
| DON'T BUY | 11.840 | Serge Depatie | In a proxy fight with the founder trying to get back the company. Not a bad company but in a bad environment with the FDA right now. | 2008-05-07 | |
| SELL | 11.310 | Duncan Stewart | (Market Call Minute.) Can't go up from here. Just had another change in management and there are no products on the horizon. | 2008-04-25 | |
| DON'T BUY | 11.150 | David Baskin | The former chairman is suing present chairman. Under investigation by the SCC. Not a stock you want to be in. | 2008-04-22 | |
| DON'T BUY | 11.050 | Michael Sprung | Earned $1.24 per share but paid $1.53 per share. Companies cannot sustain a dividend far ahead of their earnings for very long. Have had a number of problems over the last year. He wonders where the stability is going to come from. | 2008-04-15 | |
| Comment | 11.350 | Brian Acker, CA | This stock has lots of value, however bad news just keeps coming in. Model price is $24.36 but there are constant downward revisions in earnings. A lot of fat there. If you have tight stops, stick out your hand. If it broke down to $10.36, it will drop to $8.50. | 2008-04-03 | |
| DON'T BUY | 11.050 | David Burrows | The pharma sector has had a rotten time, declining earnings. This company will have worst earnings than last year. Would avoid the stock (Not value investors, don’t try to pick bottoms), in a declining environment this will perform poorly. | 2008-03-31 | |
| TOP PICK | 10.950 | Ross Healey | Getting to a yield of almost 14%, sustainable. Almost down to book value. As cheap as you want to be. Attractive to larger companies to buy. | 2008-03-26 | |
| DON'T BUY | 13.750 | Norman Levine | Not a fan of this company at all. A 2nd rate company with poor management and poor corporate governance. 10.6% dividend may not be safe. | 2008-02-26 | |
| HOLD | 13.870 | Brian Acker, CA | He has a model price of $28.88. That's 110% positive differential. This stock just begs for good news. It needs a catalyst. Thinks around this price is its bottom. | 2008-02-07 | |
| DON'T BUY | 12.950 | David Burrows | He only buys businesses that have positive dynamics and where things are getting better. This company is not in that situation. Wasn't able to perform well during reasonably good markets and is having a rougher time in more difficult markets. | 2008-01-28 | |
| WAIT | 13.200 | Bill Carrigan | Has been down for a while and has been a big disappointment. Money is flowing into healthcare and is regarded as a defensive sector. Chart looks like a falling wedge, which is bullish. Wait to see if it breaks out and in volume. | 2008-01-09 | |
| WATCH | 13.340 | Gavin Graham | FDA refused to give an extended use-release approval for its existing drug. Just announced that Havenol is going to be distributed by Johnson & Johnson (JNJ-N), so maybe it's turning. Operational side of things have improved enormously. Sold his holdings. | 2008-01-02 | |
| SELL | 13.360 | Bruce Campbell | (Market Call Minute.) Would need more of a pipeline before he would even be interested. | 2007-12-31 | |
| Comment | 13.630 | Brian Acker, CA | His model price is $30.83 giving it 125% positive differential. He sees 08 earnings at $1.54. Bad news is basically shadowing this stock. It is probably at its low, discounting any more bad news. Any good news and it should pop. Frustrating stock. | 2007-12-20 | |
| BUY | 15.020 | John Zechner | Their Welbutrin is facing competition from generic drugs. Almost 10% yield, which he feels is not sustainable. However, the stock has come down a long way and they have a pipeline that is starting to build into 2009. Have lots of cash on the balance sheet. | 2007-12-05 | |
| DON'T BUY | 14.300 | Brian Acker, CA | Model price is $29.68 but that doesn’t include recent bad news. Its next level is $13.30. This space is terrible at this time. | 2007-11-20 | |
| DON'T BUY | 14.300 | Norman Levine | This has been a hard stock to make money in. Has had some management and product issues. Investor’s confidence in the stock has been very low. | 2007-11-20 | |
| WAIT | 16.500 | Bill Carrigan | Market Call Minute - Interesting, but it keeps going down and making new lows. | 2007-11-13 | |
| SELL | 17.450 | David Baskin | There “pipeline” of new drugs is very bare. Having trouble getting market penetration with their new stuff. | 2007-09-26 | |
| DON'T BUY | 17.950 | Brian Acker, CA | Trouble written all over it. 90% differential. Needs positive news somewhere. Interesting to have in securities portfolio. | 2007-09-20 | |
| DON'T BUY | 17.850 | Gordon Higgins, CA, MBA, CFA | Got rid of their US sales force. Their key drug Welbutrin is running off protection and will have more competition in 2008. Reasonably cheap. FDA delayed one drug. There will be volatility. | 2007-09-12 | |
| DON'T BUY | 18.530 | Norman Levine | Has not been a fan of this one for many years. Current and past fundamentals have been very sketchy. Much more volatile and a higher risk than they US large pharmas. | 2007-08-29 | |
| SELL | 18.280 | David Baskin | Dividend will be at risk. Doesn't have much in the pipeline. Not sure where the growth is going to come from. | 2007-08-23 | |
| HOLD | 18.500 | Brian Acker, CA | Can't remember when this company ever had any good news. Has a negative earnings revision. His model price is $32.85, an 81% positive differential. | 2007-08-22 | |
| TOP PICK | 18.500 | Paul Gardner, CFA | 8% dividend. Good free cash flow numbers. Everyone hates the stock, so it is a true contrarian play. Trades at about 15 X earnings. The biggest risk is generics. The Wellbutin brand they own is being attacked. Have 10 new drugs coming on line. | 2007-08-22 | |
| Comment | 18.430 | Gavin Graham | With the change in dividend policy and the new CEO and the professional management, it is a different story than what it was 5 years ago. Fell off the cliff because of further generic erosion of its Wellbutrin. Going into erectile dysfunction now. Considering selling his holdings. | 2007-08-08 | |
| Comment | 21.620 | Brendan Caldwell | Has been a very frustrating stock. Not sure what is going to drive the stock going forward. | 2007-07-24 | |
| Comment | 26.600 | Bill Carrigan | Has a long trading zone from $17-$28. Volume is shrinking which usually indicates the stock is going to make a move. Suspects it will make a move to the upside. | 2007-07-10 | |
| DON'T BUY | 26.950 | David Baskin | Over 6% dividend because the company has changed from a growth story to almost like a utility. Relying on its existing drugs, which will eventually be supplanted by new drugs. | 2007-06-19 | |
| BUY | 26.170 | Brian Acker, CA | 41% positive differential. They have a hefty dividend and positive earnings. What it needs is some positive news.
A good defensive hold.
Not much downside. It's in their top 10. | 2007-06-07 | |
| Comment | 25.050 | Robert Floyd | Has been a very challenging company. In the past, earnings have been somewhat suspect. Generics have been a problem. Quite volatile. Could see a dividend cut. | 2007-03-29 | |
| DON'T BUY | 24.500 | Peter Hodson | He owns, but has been selling it, because the stock has not been doing what he wanted it to do. Pays a 7% dividend, so you would think it would do better when the market is weak, with investors looking for yield. | 2007-03-12 | |
| DON'T BUY | 24.560 | Gavin Graham | Paying off their long-term debt. The new operational management seems to be doing a good job. Settled their suits with the generics. Cleared off the US sales force. You can buy world-class pharmaceutical companies without all the problems they have. | 2007-03-06 | |
| DON'T BUY | 24.450 | David Baskin | A lot of the zip has gone out of it. | 2007-02-13 | |
| SELL | 24.320 | John Zechner | Recently sold his holdings at about $24. Their biggest drug, Welbutrin, is facing genericization very shortly. | 2007-01-22 | |
| DON'T BUY | 23.470 | David Baskin | Obviously a company in transition. Change in management. Expect it to be slower growth. Can't see any compelling reason to own it. | 2007-01-10 | |
| DON'T BUY | 24.820 | Gavin Graham | Turned itself into an income stock with their dividend increases. Did so by scrapping their expansion policy in the US and getting rid of the sales force. Major problem is too many moving parts and you’re not certain what’s coming down the pipe or what exclusivity they’ll have. | 2006-12-28 | |
| BUY | 23.990 | Brian Acker, CA | The model price is $36.29, a 50% positive differential. | 2006-12-21 | |
| BUY | 24.190 | Paul Harris, CFA | Misunderstood company. New management has done some very good things with the company. Very cheap at about 10 X earnings. Paying out a special dividend. Paying off their debt. | 2006-12-12 | |
| DON'T BUY | 24.190 | John Zechner | Giving their cash back through higher dividends and share buy back. Had hoped they would make an acquisition. Sold his holdings. | 2006-12-12 | |
| BUY | 21.640 | Ross Healey | Had a problem when its Wellbutrin got hit by generics. Now making a U-turn. Has lots of upside potential. | 2006-12-04 | |
| Comment | 21.640 | John Manley | Survived a big crunch in August, has been forming a base and starting to break out. Do some fundamental research to see what’s coming up in the biotech space. From a technical basis, it doesn’t look too bad. | 2006-12-04 | |
| DON'T BUY | 17.850 | Laura Wallace | Has a lot of problems facing it. | 2006-10-24 | |
| HOLD | 17.930 | Brian Acker, CA | The model price is $32. Analysts have ratcheted down their earnings because of the court case, but he still sees no serious dilution in his model price. The company needs a passage of time along with some good news and he thinks it would go up to about $21.80. Further bad news would make it $15.80. | 2006-10-17 | |
| BUY | 18.170 | John Zechner | He is really close to putting this one back in his portfolio. All the negative risks have already been built into the stock. Generating lots of cash. Need to do an acquisition as well as fill up their pipeline a little bit more. | 2006-10-16 | |
| BUY | 18.000 | Larry Berman CFA, CMT, CTA | Trying to find some support and build a bit of a base. One of those stocks that will go up for 4-5 months and drop back on bad news. Risk/reward is pretty compelling at this level. If you buy and it makes a lower low, don't hold. | 2006-10-11 | |
| WATCH | 16.930 | John Zechner | Getting really close to coming back to this stock. Very close to having all the bad news out of this stock. Creating cash, decent balance sheet. | 2006-09-27 | |
| SELL | 16.790 | David Burrows | Recently seeing some better performance in large pharmaceutical stocks. Sector looks attractive, but this is not one of the leading stocks. Has been significant slowdown in revenues and will be losing money in the next 4 quarters. | 2006-09-13 | |
| WEAK BUY | 16.410 | Rob Callander | A very, very difficult stock to follow. Seems to be plagued with problems. Extremely volatile. Speculative buy with a hoped-for recovery in the low to mid $20’s. | 2006-09-12 | |
| DON'T BUY | 18.600 | Laura Wallace | Facing a lot of challenges at the moment. Looks very cheap on an earnings basis but thinks earnings are going to be coming down. Would stay away until there is a little more clarity. | 2006-08-21 | |
| DON'T BUY | 17.970 | Jonathen Wellum, B. Comm, B. Sc | Doesn't like their business model. Forecasting and looking out long-term is very difficult for this business. | 2006-08-17 | |
| BUY | 17.760 | Paul Harris, CFA | The issue about generics is not a concern as it takes time for generics to take hold. Have other products in line and he likes their story. Management has done a great job of restructuring. Trades at a very low multiple. Throws off lots of free cash flow. | 2006-08-15 | |
| HOLD | 17.990 | Ross Healey | Lost a patent infringement case on their Wellbutrin allowing a generic manufacturer to produce a cheaper copy. Also, the OSC accused their chairman of breaching security rules. Fundamental value doesn't look all that bad. If you own, wait to see how the market shakes out. | 2006-08-03 | |
| DON'T BUY | 17.700 | Brian Acker, CA | This is not in the TSE100 which he requires for it to qualify for his Canada Focus fund. May stop at $15.50. Will be interested to see what the earnings do. | 2006-08-02 | |
| DON'T BUY | 25.020 | John Zechner | A little concerned with their key drug, Wellbutin, coming off patent. Could have some generic competition sooner than expected. Their new drug Alltrun ER has started up a little bit slower than expected. A little concerned on the next couple of quarters on earnings growth. Has sold his position. | 2006-07-31 | |
| DON'T BUY | 25.560 | Gavin Graham | Operational side has improved enormously. New CEO has done a good job. Their stent technology seems to work. Only 2% yield, where some of the other larger Biotech's are safer and give you a better yield. | 2006-07-06 | |
| DON'T BUY | 25.270 | David Driscoll | Was a one trick pony and is trying to become a two trick pony. There are no guarantees so there is a risk. Had accounting problems which created a drop in the stock. | 2006-06-29 | |
| DON'T BUY | 29.190 | David Driscoll | Turning itself from being a 1 trick pony into more of a diversified pharmaceutical company. There is a counter party risks as the credit rating is only BB high. Would rather see them spending all their time on research and development rather than seeing them fend off a lawsuit or get aggressive. | 2006-05-08 | |
| DON'T BUY | 28.390 | David Baskin | This company tends to move on news. Not crazy about the governance of the company. | 2006-04-18 | |
| BUY | 28.390 | Paul Harris, CFA | Cheap on at valuation basis. Have great cash flow. Very little debt. Has always been an undervalued franchise since the stock collapsed. Sold off a lot of their US sales franchise and really cut back on their cost structure. | 2006-04-18 | |
| BUY | 28.290 | Brian Acker, CA | He has a model price of $43.60 which is a 56% positive differential. | 2006-03-29 | |
| WEAK BUY | 30.950 | Michael Sprung | Earnings beat analysts’ estimates, but only by a few cents. Has done well over the last year. The question is, what is the multiple going forward. Based on some analysts estimations, it could be 16 X, which isn't rich but the company would have to make big jumps to get there. | 2006-03-23 | |
| DON'T BUY | 29.730 | Gavin Graham | New management has seems to have cleaned it up and turned it around. Their technology does work. Hedge funds are creating problems with legal issues, etc. There are better world class drug companies available. | 2006-03-20 | |
| HOLD | 29.500 | Robert McWhirter | Biovail is in the top 15% of the data base. It has had 14% earnings growth. It is a reasonable price. He does not own currently, sold it because of the concerns in the market . Interesting, yet cheap. Hold or add to on a pull back. | 2006-03-13 | |
| BUY | 28.760 | Brian Acker, CA | Even with Citigroups downgrade, he likes it. Putting the Citigroups earnings estimate in their model price remained the same. It doesn't qualify for canafocus(sp?) (not top 100 in TSE) so they can't buy it. But it sounds like they would otherwise. | 2006-02-14 | |
| PAST TOP PICK | 27.420 | Brian Acker, CA | (A Top Pick Nov 23/05. Down 1.7%.) An analyst from Citigroup put a sell signal on which knocked the stock down. Still sees a lot of value in this stock with a 46% positive differential. | 2006-02-07 | |
| BUY | 27.140 | Ross Healey | A Citi Group analyst downgraded the stock so the stock dropped. The consensus earnings forecast since the downgrade has been good and firm. His fair market value is about $60. He feels the stock can do much better. | 2006-02-06 | |
| HOLD | 28.770 | Paul Harris, CFA | Really like this one when it was around $16. The market had been down on it because of their products looking out and the management in general. A lot of those things have changed. Probably fairly valued now. There is more upside, but wouldn't buy. | 2006-01-20 | |
| BUY | 27.500 | Ross Healey | Thinks it bottomed when it got down to the $17/18 area with all the bad news built into the stock. There’s a couple of accounting issues, but doesn’t think they are very serious. | 2005-12-13 | |
| WEAK BUY | 27.600 | Jim Huang | Not a stock for the fainthearted. They're doing quite well right now with good partners and good market share. Their problem is generic products that come in and take away market share driving margins down. Have to keep coming out with good products. Trading at a reasonable level. Probably a 15/20% upside for the next couple of years.' | 2005-12-06 | |
| DON'T BUY | 28.260 | Ron Meisels | The stock has recently managed to run right up against the 200 day moving average trend line and professionals sold. There has been some base building, so there is now a fight between the people who are saying there is a base and those who are saying the stock is fighting the down trend line. | 2005-12-01 | |
| BUY | 27.090 | Bill Carrigan | Long-term chart shows a falling wedge. When you see, this pattern, you can buy into it. It's usually a signal of a long-term trend range. | 2005-11-28 | |
| TOP PICK | 27.880 | Brian Acker, CA | His model price is $42, a 56% differential. | 2005-11-23 | |
| SELL | 26.370 | Bruce Campbell | Has always found it expensive and risky. Has had some good news which is already in the stock, so not surprised to see it pull back a little bit. | 2005-11-21 | |
| WAIT | 31.870 | Mark Jackson, CFA | Has ahd a very good move in the last couple of months with fairly good announcements and the stock has had a step up in terms of valuation. Wouldn't chase it here, but would wait for a little bit of weakness in the price. | 2005-11-15 | |
| BUY | 31.850 | Brian Acker, CA | Has a model price of $39.55 which is a differential of today's close of 24%. Stiill some room to grow. | 2005-11-14 | |
| WEAK BUY | 30.500 | Rob Callander | Because of all the problems this stock has had, he is now selling his holdings. Will buy US companies in the future where there’s a much bigger variety. | 2005-11-10 | |
| SELL | 30.250 | David Baskin | Has had a terrific run with its one dose a day pain killer. Not a fan of the management and the ownership. Prefers others. Not a bad exit point. | 2005-11-08 | |
| WEAK BUY | 27.360 | John Sinkins, CFA | Has been a big winner on its drug Tramadol. Would be a little cautious at this price. | 2005-10-25 | |
| PAST TOP PICK | 25.800 | Brian Acker, CA | (Top Pick Aug 4/05. Up 23%.) Still likes. | 2005-10-20 | |
| DON'T BUY | 26.650 | Ron Meisels | Recently had a rally from $21 to $28 and is probably ahead of itself at this time. If you own, use a $25 stop/loss. | 2005-10-17 | |
| BUY on WEAKNESS | 26.010 | Ross Healey | Has pretty well lived through all the serious threats to its ongoingness as a business. Great drug technology and they now have a nice new slow release drug that will be a big seller. Buy on any weakness. | 2005-10-13 | |
| WEAK BUY | 26.900 | Larry Berman CFA, CMT, CTA | An interesting play. Came unglued over the last number of years, but has had a technical breakout. Finally broke through the 200 day moving average and have seen a higher high. Expect it to go higher. Would like to see it drop a bit at a test gap before buying, around the $24/25 area. | 2005-09-28 | |
| BUY | 26.450 | Brian Acker, CA | Feels his model price is about 40% higher than the current price. Dirt cheap. New management is getting credibility. They have announced a new drug. | 2005-09-21 | |
| DON'T BUY | 25.450 | David Baskin | Doesn't trust their corporate governance. Thinks there stock is blown up right now. | 2005-09-19 | |
| TOP PICK | 26.250 | Ross Healey | Have some terrific medical technology. Just got FDA approval for its Tremadol painkiller. Probably has easy potential to reach $32, but wouldn't be surprised if it went much higher. | 2005-09-14 | |
| DON'T BUY | 21.460 | David Baskin | Its glory days are 2 years behind it now. Will take a while for it to go back. Fully valued. | 2005-09-08 | |
| PAST TOP PICK | 21.460 | Brian Acker, CA | (A Top Pick June 9/05. Up 7%.) Likes this one. Dirt cheap. | 2005-09-07 | |
| BUY | 21.740 | Paul Harris, CFA | They've restructured and got rid of their US sales force which was a very important decision. Have made a lot of effort to change their corporate financing. The issue is that they have one drug which is a large percentage of their overall revenue. Very cheap and throws off lots of free cash and trades at $1.75/1.85 on earnings. | 2005-08-12 | |
| BUY | 21.540 | Bill Carrigan | This one has probably bottomed. Has a lot of support at around $16/17. | 2005-08-09 | |
| DON'T BUY | 21.230 | Gavin Graham | Sold it when it started missing on its earnings estimates. Have an interesting technology. Has been flat over the last year. Getting rid of their US sales force. Will look at it again when it's had a couple of years of successful numbers. | 2005-08-08 | |
| TOP PICK | 21.950 | Brian Acker, CA | (A Top Pick Jun 9/05. Up 4%.) Has a model price of $40 for some time and the stock is going up. There is value here. The stock gets no respect. Looking at earnings estimates, going out in '05 and '06, it's a cheap stock. | 2005-08-04 | |
| DON'T BUY | 18.650 | John Sinkins, CFA | Probably fairly valued. There is some question about the speed of developing new drugs. Accounting issues are now OK. | 2005-07-18 | |
Experts that have talked about Biovail Corp.
Rss Top Picks Feed